Vinati Organics Ltd Q4 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/5pqyyqe3ey5sr2ks2q7nd78z.pdf

Key Takeaways


ATBS: Recovery, Constraints & Expansion

Vinati Saraf Mutreja: "Today, we are seeing good demand for the higher purity ATBS. When that is in demand, then you can produce less. There is capacity constraint."

VOPL Portfolio: Commissioned but Not Yet Contributing

Vinati Saraf Mutreja: "…due to delivery constraints of some of the equipment that we have ordered from Europe the plant I do not think will start before December or January. That is what realistically it is looking like."

Butylphenols & Antioxidants: The Margin-Mix Story

Vinati Saraf Mutreja: "I expect to maintain or to see EBITDA margins in the range of 26% because this is how the product mix is going to stay going forward. Butylphenols, antioxidant businesses they have a different margin profile."

Competitive Position & China Risk

Vinati Saraf Mutreja: "I don't see China as a major threat to at least most of the other product segments that we are into."

New Product Strategy & Growth Algorithm

Vinati Saraf Mutreja: "We keep adding two to three products every year. First three years, four years back we added butyl phenols and we added antioxidants. Now we will add the whole range of products in VOPL which also includes isoamylene derivatives, five, six new products."

Guidance & Commitments

CommitmentSpecificsTimeline
ATBS sales growthDouble-digit growthFY25
ATBS expansion completionNew line commissionedSecond half of FY25 (not before Dec/Jan)
ATBS new line full utilizationFull capacity utilization achievedAt least three years after commissioning
VOPL meaningful revenueRevenue contributions of significance beginH2 FY25
VOPL FY25 salesMaybe ₹50 crores, not even ₹100 croresFY25
VOPL peak revenue~₹500 crores (1:1 asset turnover)~3 years from today
VOPL other products commissioningAnisole, 4-MAP, TAA, PTAP commissionedH2 FY25
Antioxidants capacity utilizationAt least 50% utilizationFY25
Revenue CAGR~20%Over next 3 years
EBITDA marginMaintain around 26%Going forward
PAT growthAt least 20-25% higher than FY24FY25
Butylphenols growthContinue delivering growthNext financial year
Customized products growthGood growth expectedComing years
IBB performanceSame figure as FY24FY25
Niche product basket (Japanese customers)Remain more or less the sameFY25

Key Metrics

MetricQ4 FY24
Total income₹560 cr, +23% QoQ from ₹457 cr in Q3 FY24
EBITDA₹160 cr, +29% QoQ from ₹123 cr in Q3 FY24
PAT₹104 cr, +30% QoQ from ₹77 cr in Q3 FY24
Total income (full year FY24)~₹1,930 cr, -9% YoY from ~₹2,100 cr in FY23
EBITDA (full year FY24)~₹509 cr, -18% YoY from ~₹620 cr in FY23
PAT (full year FY24)~₹323 cr, -23% YoY from ~₹419 cr in FY23
EBITDA margin guidance~26%, expected to be maintained going forward
Revenue CAGR guidance~20% over the next 3 years
PAT growth guidance (FY25)at least 20–25% higher than FY24
ATBS revenue contribution~32% of total revenue in FY24, similar in Q4
ATBS global market share60–65%, unchanged
ATBS capacity utilizationclose to 100% on existing capacity, up from 65% in the prior quarter
Butyl phenols sales (FY24)~₹300 cr
Butyl phenols capacity utilization65–70% in FY24, close to 100% in Q4 FY24
Antioxidant business revenue (FY24)~₹130 cr
Antioxidant capacity utilization~25% in FY24, expecting at least 50% in FY25
Capex incurred (FY24)~₹360 cr, across Vinati Organics and VOPL
Capex guidance (FY25)~₹550 cr, including subsidiary
VOPL total capex~₹500 cr
VOPL expected sales (FY25)~₹50 cr, meaningful revenue only from H2 FY25
VOPL peak revenue potential~₹500 cr, achievable in 3 years
Solar power commissioned~33 MW